Professional Documents
Culture Documents
9-Test Finds Residual Medulloblastoma in Kids After Treatment - National Cancer Institute
9-Test Finds Residual Medulloblastoma in Kids After Treatment - National Cancer Institute
Being able to identify residual disease sooner than is possible with other methods could be very important
for children with medulloblastoma, the researchers who led the study believe, giving doctors precious time
to treat these patients with more aggressive therapy.
“Parents will tell you that once they reach the end of therapy, they get incredibly nervous because they’re
just waiting and observing” to see if their child’s cancer comes back, said Giles W. Robinson, M.D., of St.
Jude Children’s Research Hospital, one of the study’s leaders.
“If you have a test that can say you’re truly free of the disease at the end of treatment, that adds a huge
amount of reassurance,” he said. But if the test shows you have evidence of residual disease, “then maybe
that shouldn't be the end of therapy.”
In the new study, researchers analyzed samples of cerebrospinal fluid collected at various points during and
after treatment from children with medulloblastoma. Patients whose cancer came back, they found, were
much more likely to have cell-free DNA with cancer-related characteristics in the fluid samples than those
who remained cancer free.
“This study is groundbreaking,” said Marta Penas-Prado, M.D., of the Neuro-Oncology Branch in NCI’s Center
for Cancer Research, who was not involved with the study. “It opens the door to a highly sensitive method of
confirming the presence of tumor cells when imaging scans or conventional spinal taps aren’t conclusive.”
Dr. Robinson noted that more studies are needed to validate the test in additional groups of patients before
we can determine how it might be used to direct treatment.
Doctors currently treat medulloblastomas with surgery, followed by radiation and chemotherapy. But in up
to one-third of children with medulloblastoma, the cancer comes back after treatment.
MRI scans can help doctors see when a tumor has come back, but imaging cannot detect small amounts of
remaining tumor cells—known as measurable residual disease, or minimal residual disease—that can
indicate that treatment has not eliminated the cancer entirely. Also, imaging can be difficult to interpret,
especially in patients who have undergone previous surgeries and radiation.
“There are things like scar tissue from surgery and from radiation that can look exactly the same as a
tumor,” said Dr. Penas-Prado.
As a result, during the period of treatment after surgery, repeated spinal taps—in which a needle is inserted
between vertebrae (under anesthesia) to collect samples of cerebrospinal fluid for analysis—are typically
performed to look for any cancer cells that remain.
“The cerebrospinal fluid is currently used to identify metastatic tumor cells under the microscope,” said one
of the study’s lead researchers, Paul Northcott, Ph.D., also of St. Jude. “But even in patients who have active
disease, we often fail to detect tumor cells in the cerebrospinal fluid. It's not a very sensitive test.”
Many studies have investigated whether identifying cancer-related changes in bits of genetic material in the
blood or other body fluids can help to detect cancer recurrences sooner than other methods. The St. Jude
team wanted to see if this approach could be used as a marker of measurable residual disease in
cerebrospinal fluid from kids with medulloblastoma.
“What we have seen in diseases like leukemia is that, if you can detect signs of residual disease really early
on, then you can make some treatment adjustments and actually improve the prognosis of those patients
and potentially prevent relapse,” said Dr. Robinson.
“There's a lot of interest in the concept of liquid biopsy for cancer, but the technology hadn’t been optimized
for pediatric brain tumors,” said Dr. Northcott. “Through careful scientific trial and error and optimization at
the lab bench, we found a protocol that can reliably identify the genomic variations characteristic of
medulloblastoma.”
What’s more, in 32 children whose MRIs showed no signs of cancer after radiation therapy but whose
disease eventually returned, the test found measurable residual disease in half of these patients at least 3
months, and up to 2 years, earlier than imaging did.
“We could see that the disease was starting to re-emerge in that fluid well before we could see it on an MRI,”
Dr. Robinson said. “This offers us an opportunity to intervene earlier than ever before.”
Spotting the return of disease this early also has scientific potential, Dr. Northcott said. With further
improvements in technology and as researchers gain more experience in analyzing cell-free DNA, he
continued, “we believe we will be able to make more molecular discoveries [that can explain] why the
disease has not gone away.”
“It turns out in this study that the tumors with the Sonic Hedgehog molecular subtype were less likely to
shed DNA into the cerebrospinal fluid,” she said. “That means this [test] may be less applicable for adults
with medulloblastoma than for children.”
In an accompanying editorial, John R. Prensner, M.D., Ph.D., and Scott L. Pomeroy, M.D., Ph.D., of the Broad
Institute of Massachusetts Institute of Technology and Harvard University noted that analyzing cerebrospinal
fluid may be less practical for patients not being treated as part of a clinical trial where cerebrospinal fluid is
collected at different time points.
Although further research is needed, they continued, “the lessons gained from this work will inevitably
catalyze important conversations regarding the development and standardization of measurable residual
disease assays for patients with medulloblastoma.”
If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about
copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute
as the source and link to the original NCI product using the original product's title; e.g., “Test Detects Early Signs of
Remaining Cancer in Kids Treated for Medulloblastoma was originally published by the National Cancer Institute.”
Featured Posts
Surgery May Be an Option When Ovarian Cancer Returns
January 12, 2022,
by NCI Staff
Categories
Biology of Cancer
Cancer Risk
Childhood Cancer
Clinical Trial Results
Disparities
FDA Approvals
Global Health
Leadership & Expert Views
Prevention
Prognosis
Screening & Early Detection
Survivorship & Supportive Care
Technology
Treatment
Archive
2022
January (6)
2021
December (7)
November (4)
October (7)
September (9)
August (6)
July (7)
June (7)
May (7)
April (8)
March (7)
February (6)
January (6)
2020
December (7)
November (7)
October (8)
September (6)
August (7)
July (9)
June (8)
May (8)
April (10)
March (7)
February (7)
January (7)
2019
December (6)
November (7)
October (8)
September (8)
August (6)
July (8)
June (6)
May (9)
April (7)
March (10)
February (9)
January (6)
2018
December (9)
November (9)
October (9)
September (11)
August (9)
July (9)
June (12)
May (9)
April (10)
March (11)
February (11)
January (10)
2017
December (11)
November (13)
October (11)
September (12)
August (14)
July (9)
June (13)
May (10)
April (9)
March (10)
February (9)
January (7)
2016
December (8)
November (8)
October (9)
September (11)
August (8)
July (9)
June (12)
May (13)
April (10)
March (10)
February (13)
January (9)